Diabetes

Review compares outcomes, safety for once-weekly GLP-1RAs

(HealthDay)—Cardiometabolic outcomes and safety vary among different once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) treatments, according to a review published online Dec. 8 in the Annals of Internal Medicine.

page 43 from 612